 |
53 Diseases |  |
17 Trials |
|
17 Trials |  |
785 News |  |
| «12...3456789101112131415 |
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension (clinicaltrials.gov) - Aug 21, 2014
P2, N=75, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH (clinicaltrials.gov) - Aug 7, 2014
P2, N=10, Recruiting, Sponsor: University of Ottawa Heart Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: PATENT-2: BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jul 30, 2014
P3, N=396, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> May 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women (clinicaltrials.gov) - Jul 30, 2014
P1, N=24, Recruiting, Sponsor: Bayer
Trial primary completion date: Aug 2014 --> May 2016 Not yet recruiting --> Recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial initiation date, Trial primary completion date: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Jul 24, 2014
P2, N=36, Not yet recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: Feb 2015 --> Aug 2015
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P4 trial: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Jul 16, 2014
P4, N=100, Not yet recruiting, Sponsor: Bayer
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Relative Bioavailability Study (clinicaltrials.gov) - Jul 12, 2014
P1, N=24, Recruiting, Sponsor: Bayer
Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: Feb 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients (clinicaltrials.gov) - Jun 24, 2014
P2, N=36, Not yet recruiting, Sponsor: Bayer
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=900, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (clinicaltrials.gov) - Jun 17, 2014
P2, N=23, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women (clinicaltrials.gov) - Jun 7, 2014
P1, N=24, Not yet recruiting, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Relative Bioavailability Study (clinicaltrials.gov) - Jun 5, 2014
P1, N=24, Not yet recruiting, Sponsor: Bayer
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - Jun 4, 2014
P2, N=120, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (clinicaltrials.gov) - May 15, 2014
P2, N=20, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> May 2014
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial initiation date: EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (clinicaltrials.gov) - May 15, 2014
P=N/A, N=900, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Apr 2014 --> May 2014 Initiation date: Apr 2014 --> May 2014
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (clinicaltrials.gov) - May 15, 2014
P2, N=20, Recruiting, Sponsor: Bayer
Initiation date: Apr 2014 --> May 2014 Trial completion date: Apr 2014 --> May 2014
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 13, 2014
P2, N=120, Not yet recruiting, Sponsor: Bayer
- ||| Adempas (riociguat) / Bayer
Clinical: JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=420, Not yet recruiting, Sponsor: Bayer
- Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH (clinicaltrials.gov) - Mar 19, 2014
P2, N=10, Not yet recruiting, Sponsor: University of Ottawa Heart Institute
- ||| Adempas (riociguat) / Bayer
Clinical: EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=900, Not yet recruiting, Sponsor: Bayer
- |||||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Mar 13, 2014
P3, N=70, Recruiting, Sponsor: Bayer
Trial completion date: Apr 2014 --> May 2014 Not yet recruiting --> Recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial termination: DILATE: A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (clinicaltrials.gov) - Feb 26, 2014
P2, N=39, Terminated, Sponsor: Bayer
Not yet recruiting --> Recruiting Completed --> Terminated; Recruitment was only stopped after the statistical power of the study was reached and the study objectives could be met despite the premature discontinuation.
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID (clinicaltrials.gov) - Jan 27, 2014
P1, N=7, Completed, Sponsor: Bayer
Completed --> Terminated; Recruitment was only stopped after the statistical power of the study was reached and the study objectives could be met despite the premature discontinuation. N=10 --> 7
- Adempas (riociguat) / Bayer, Merck (MSD)
New P4 trial: Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude (clinicaltrials.gov) - Dec 29, 2013
P4, N=20, Not yet recruiting, Sponsor: Richard Moon
- |||||||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P3 trial: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Dec 9, 2013
P3, N=70, Recruiting, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (clinicaltrials.gov) - Oct 15, 2013
P2, N=20, Recruiting, Sponsor: Bayer
N=10 --> 7 Not yet recruiting --> Recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (clinicaltrials.gov) - Aug 19, 2013
P2, N=20, Recruiting, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: PATENT PLUS: Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (clinicaltrials.gov) - May 20, 2013
P2, N=18, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P3 trial: Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Feb 4, 2013
P3, N=0, Available, Sponsor: Bayer
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: PATENT PLUS: Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (clinicaltrials.gov) - Oct 16, 2012
P2, N=18, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=36 --> 18
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: CHEST-2: BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (clinicaltrials.gov) - Aug 8, 2012
P3, N=237, Active, not recruiting, Sponsor: Bayer
N=36 --> 18 Enrolling by invitation --> Active, not recruiting
- ||||||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: CHEST-1: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (clinicaltrials.gov) - Aug 5, 2012
P3, N=261, Completed, Sponsor: Bayer
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: PATENT-2: BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jul 15, 2012
P3, N=396, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: PATENT-1: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jun 3, 2012
P3, N=445, Completed, Sponsor: Bayer
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Relative Bioavailability and Food Effect Study (clinicaltrials.gov) - Apr 19, 2012
P1, N=32, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: LEPHT: A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (clinicaltrials.gov) - Feb 13, 2012
P2, N=201, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Relative Bioavailability and Food Effect Study (clinicaltrials.gov) - Dec 7, 2011
P1, N=32, Completed, Sponsor: Bayer
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial withdrawal: CORONARIES: Coronary Vasomotor Response After Riociguat Exposure (clinicaltrials.gov) - Nov 13, 2011
P2, N=0, Withdrawn, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: CORONARIES: Coronary Vasomotor Response After Riociguat Exposure (clinicaltrials.gov) - Nov 13, 2011
P2, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Withdrawn N=20 --> 0